List of Excipients in Branded Drug EVOXAC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cosette Pharmaceuticals Inc	EVOXAC	cevimeline hydrochloride	0713-0883	HYDROXYPROPYL CELLULOSE
Cosette Pharmaceuticals Inc	EVOXAC	cevimeline hydrochloride	0713-0883	LACTOSE MONOHYDRATE
Cosette Pharmaceuticals Inc	EVOXAC	cevimeline hydrochloride	0713-0883	MAGNESIUM STEARATE
STAT RX USA LLC	EVOXAC	cevimeline hydrochloride	16590-859	HYDROXYPROPYL CELLULOSE
STAT RX USA LLC	EVOXAC	cevimeline hydrochloride	16590-859	LACTOSE MONOHYDRATE
STAT RX USA LLC	EVOXAC	cevimeline hydrochloride	16590-859	MAGNESIUM STEARATE

Last updated: August 7, 2026

EVOXAC is the brand name for cevimeline hydrochloride hydrate, an oral muscarinic agonist used to treat dry mouth associated with Sjögren's syndrome. Its commercial formulation is a 30 mg immediate-release hard gelatin capsule with a conventional excipient system. The strongest excipient opportunities are generic substitution, lactose-free and animal-origin-free capsules, improved moisture control, and differentiated oral delivery systems. The active ingredient and core formulation appear to have limited remaining U.S. patent barriers, so regulatory execution, supply reliability, tolerability, and manufacturing cost are more important than patent exclusivity.

EVOXAC Excipient Strategy and Commercial Opportunities for Cevimeline

What is EVOXAC and how is it formulated?

EVOXAC contains cevimeline hydrochloride hydrate, a cholinergic agonist that increases salivary and lacrimal secretion. In the United States, EVOXAC is approved as a 30 mg oral capsule for the treatment of symptoms of dry mouth in patients with Sjögren's syndrome. The product is administered three times daily, creating a commercial rationale for capsule manufacturability, dose consistency, swallowability, and adherence support. [1]

The U.S. reference product is an immediate-release hard gelatin capsule. Its listed inactive ingredients include lactose, hydroxypropyl cellulose, magnesium stearate, gelatin, titanium dioxide, yellow ferric oxide, and capsule printing ink. The precise excipient composition can vary by market and manufacturing site, so the approved local label remains the controlling source for product development. [1,2]

Attribute	EVOXAC reference product
Active ingredient	Cevimeline hydrochloride hydrate
Strength	30 mg cevimeline equivalent per capsule
Dosage form	Immediate-release hard gelatin capsule
U.S. indication	Dry mouth symptoms associated with Sjögren's syndrome
Administration	Oral, three times daily
Key excipients	Lactose, hydroxypropyl cellulose, magnesium stearate, gelatin, titanium dioxide, yellow ferric oxide
Primary formulation risks	Moisture sensitivity, capsule shell variability, lactose intolerance, gelatin-origin restrictions
Main commercial benchmark	Therapeutic equivalence to the reference capsule

The product is not a biologic. Biosimilar regulation does not apply. A competing product would generally be developed as a conventional generic capsule through an abbreviated new drug application, assuming the sponsor can demonstrate pharmaceutical equivalence and bioequivalence.

What excipients are used in EVOXAC capsules?

The reference formulation uses a standard capsule-fill system rather than a complex modified-release platform.

Lactose

Lactose is a low-cost filler with broad pharmaceutical use. It supports capsule fill weight and powder handling but creates several commercial constraints:

• It is unsuitable for patients avoiding lactose.
• It can complicate positioning in a "clean-label" or lactose-free product.
• It may require tighter control of residual moisture and particle-size distribution.
• It can create compatibility concerns in formulations containing reactive amine-containing drugs, although the relevance must be confirmed through stability testing rather than assumed.

A generic sponsor could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch, or a co-processed excipient. The best substitute depends on bulk density, flow, capsule fill weight, dissolution, and the ability to match the reference product's in vitro and in vivo performance.

Hydroxypropyl cellulose

Hydroxypropyl cellulose can act as a binder and improve powder cohesion. Its use supports capsule-fill uniformity but may affect wetting and dissolution if the concentration or grade changes materially. A replacement with povidone, low-substituted hydroxypropyl cellulose, or a different cellulose derivative is possible, but the formulation must preserve rapid release.

Magnesium stearate

Magnesium stearate is a conventional lubricant. Excessive lubrication can slow wetting and dissolution, particularly in formulations with hydrophobic drug particles or high lubricant exposure. A generic formulation should establish a controlled blending endpoint and evaluate the effect of lubricant concentration and mixing time on dissolution.

Gelatin capsule shell

Gelatin provides a low-cost, widely accepted capsule shell. It also creates the clearest differentiation opportunity:

• Animal-origin-free capsules can address vegetarian, religious, and institutional procurement requirements.
• Hydroxypropyl methylcellulose capsules can improve positioning for patients avoiding animal-derived materials.
• HPMC capsules can have different moisture-transfer properties and may alter product stability.
• Color and opacity changes can affect product identification and regulatory comparability.

An HPMC shell would usually require a full evaluation of moisture sorption, brittleness, dissolution, fill-machine compatibility, and storage conditions.

Titanium dioxide and iron oxide colorants

Colorants provide product identification and brand continuity. A generic sponsor could retain a similar color or select an alternative color system. Removing titanium dioxide or changing iron-oxide content may support market access in jurisdictions with tighter scrutiny of colorants, but the change can affect capsule appearance, light protection, and identification.

What excipient strategy is best for a generic EVOXAC product?

The lowest-risk strategy is a conventional immediate-release capsule that closely follows the reference product's critical quality attributes. A higher-value strategy is a lactose-free, animal-origin-free capsule that remains bioequivalent and retains the same 30 mg strength.

Strategy	Proposed excipient approach	Commercial value	Development risk
Reference-like generic	Lactose, cellulose binder, magnesium stearate, gelatin capsule	High probability of approval; low cost	Low
Lactose-free generic	Microcrystalline cellulose or mannitol replacing lactose	Access to lactose-avoidant patients and institutions	Low to moderate
Animal-origin-free generic	HPMC capsule shell	Differentiation in selected markets	Moderate
Colorant-reduced capsule	Simplified capsule shell and printing system	Cleaner label and supply flexibility	Low to moderate
Modified-release capsule	Polymer matrix or multiparticulate system	Potential adherence benefit	High
Orally disintegrating product	Mannitol-based tablet or rapidly dispersible dosage form	Swallowing convenience	High
Liquid formulation	Solubilized or suspension product	Use in selected patients with swallowing difficulty	High

The reference-like product is likely to have the strongest cost and approval profile. The differentiated product has greater commercial upside but introduces more comparability work and a greater risk of dissolution or bioequivalence failure.

What formulation patents protect EVOXAC?

Cevimeline's original composition-of-matter and use-related patent protection is old relative to the 2000 U.S. approval of EVOXAC. The product is therefore unlikely to have meaningful unexpired U.S. composition-of-matter exclusivity in the conventional generic-development period. The FDA Orange Book is the controlling source for current listed patents and regulatory exclusivity. [3]

The practical protection profile is:

Protection category	Commercial assessment
Active ingredient patent	Historical protection; expected to be expired in the United States
Original oral capsule formulation	Conventional technology with limited differentiation
Method-of-use protection	Historical use claims may exist, but current enforceability depends on jurisdiction and claim status
U.S. Orange Book patents	Must be checked against the current FDA listing for NDA 20-989
Regulatory exclusivity	Original approval exclusivity has expired
Biosimilar barrier	Not applicable because cevimeline is a small molecule
Manufacturing know-how	More relevant than patent exclusion for supply and quality control

Formulation patents may still matter outside the United States, especially if a sponsor seeks protection for a new dosage form, salt, polymorph, particle-size distribution, taste-masking system, or controlled-release formulation. A patent on a new delivery system would not necessarily block a conventional immediate-release generic capsule.

When does EVOXAC lose exclusivity and what is the generic entry risk?

EVOXAC's original U.S. regulatory exclusivity has expired, and the product is commercially exposed to generic competition. The key generic route is an ANDA referencing the approved capsule. A Paragraph IV certification would become relevant only if the current Orange Book contained an unexpired patent listed against the relevant product. [3,4]

Generic launch scenarios

1. Single conventional ANDA entrant: The most likely initial scenario is a 30 mg immediate-release capsule using a reference-like excipient system.
2. Multiple ANDA entrants: Competition would probably shift rapidly toward price, wholesaler access, shortage avoidance, and contract manufacturing reliability.
3. Differentiated generic: A lactose-free or HPMC-capsule product could command limited channel preference but would remain subject to generic substitution rules.
4. 505(b)(2) reformulation: A liquid, orally disintegrating, or extended-release product could pursue a different regulatory strategy but would require clinical or bridging evidence and a clear patient benefit.
5. Market withdrawal or limited supply: A niche product may experience supply instability if only a small number of manufacturers remain active. This creates an opportunity for a reliable secondary supplier even without premium pricing.

Because cevimeline is used for a chronic condition and is dosed three times daily, adherence and availability have commercial importance. The principal risk to the branded product is substitution by lower-priced capsules rather than a biosimilar-style challenge.

Which excipient substitutions offer the strongest commercial opportunity?

Lactose-free formulation

A lactose-free capsule is the most practical differentiation pathway. The formulation could use microcrystalline cellulose, mannitol, or a co-processed filler-binder. The sponsor would need to match:

• Capsule fill weight
• Powder flow
• Content uniformity
• Disintegration
• Dissolution profile
• Stability under accelerated and long-term conditions
• Bioequivalence exposure parameters

Mannitol can improve mouthfeel and provide a cleaner patient-positioning message, but it may alter bulk density and moisture behavior. Microcrystalline cellulose often offers better capsule-fill robustness but can produce different dissolution behavior depending on grade and compaction.

Animal-origin-free capsule

An HPMC shell can support institutional and international market access. This option is commercially attractive where gelatin restrictions affect formularies or procurement. The key risks are shell brittleness, moisture transfer, machine performance, and potential changes in drug release.

Low-moisture formulation

Cevimeline hydrochloride hydrate should be evaluated for moisture sensitivity, solid-state changes, and interaction with the capsule shell. A low-moisture excipient system, high-barrier blister, or desiccant-supported bottle may reduce stability risk. Packaging changes can be more valuable than a complex excipient change if the principal failure mode is moisture uptake.

Swallowability and adherence

A 30 mg capsule taken three times daily creates a basis for patient-friendly delivery. Potential products include smaller capsules, sprinkle capsules, rapidly dispersible tablets, or once-daily modified-release products. The commercial benefit is uncertain because a new dosage form would face a higher development burden and could require clinical justification.

What FDA regulatory pathway applies to EVOXAC generics?

A conventional 30 mg cevimeline capsule would generally use the ANDA pathway. The sponsor would need to establish pharmaceutical equivalence to the reference listed drug and demonstrate bioequivalence under FDA requirements. Excipient differences are permitted when they do not create safety, performance, or bioequivalence problems. [4,5]

The principal CMC package would include:

• Drug substance identity, purity, and solid-state characterization
• Excipient specifications and supplier qualification
• Blend uniformity and capsule-fill controls
• Dissolution method development and comparative profiling
• Stability data
• Container-closure qualification
• Microbiological controls where applicable
• Capsule shell composition and colorant documentation
• Manufacturing process validation

A 505(b)(2) application is more relevant to a new dosage form or route than to a routine capsule substitution. It could support an improved product, but it would not be the preferred route for a low-cost generic.

What manufacturing and intellectual-property barriers affect cevimeline?

The main barriers are operational rather than exclusivity-based.

Drug substance supply

Cevimeline is a niche active pharmaceutical ingredient. Limited API suppliers can create risks in qualification, capacity, impurity control, and change management. A sponsor should secure more than one qualified source where possible and evaluate route-specific impurities, residual solvents, elemental impurities, and polymorphic or hydrate behavior.

Formulation reproducibility

A reference-like formulation is technically straightforward, but capsule content uniformity can become a risk at low fill weights or when powder density differs between excipient suppliers. Process controls must address segregation, blend sampling, lubricant distribution, and capsule weight variation.

Packaging

A high-barrier blister or bottle may protect against moisture more effectively than a low-cost packaging configuration. Packaging selection can affect product cost, shelf life, and pharmacy handling. This is a meaningful commercial lever for a product taken chronically.

Patent and know-how position

Expired composition patents do not eliminate freedom-to-operate issues. A sponsor must still screen current formulation, manufacturing, and delivery-system patents in the relevant jurisdictions. For a conventional capsule, the more significant competitive barrier is likely to be regulatory approval and dependable supply rather than a blocking patent.

How does EVOXAC compare with competing dry-mouth therapies?

Cevimeline competes with pilocarpine, saliva substitutes, gels, sprays, lozenges, and nonprescription oral-moisturizing products. Pilocarpine is the closest systemic pharmaceutical competitor because it is also a muscarinic agonist used for salivary stimulation. [6]

Product category	Route	Excipient opportunity	Competitive position
Cevimeline capsule	Oral systemic	Lactose-free shell, HPMC capsule, adherence-oriented dosage form	Prescription niche
Pilocarpine tablet	Oral systemic	Conventional generic optimization	Direct systemic competitor
Artificial saliva	Local oral	Flavor, viscosity, preservative, spray performance	Non-systemic alternative
Oral gel or lozenge	Local oral	Mucoadhesive polymers, sweeteners, flavor systems	Convenience-focused
Dry-mouth spray	Local oral	Solubilizers, propellants or pump systems	Fast local relief

Cevimeline's commercial opportunity is strongest where systemic therapy is clinically appropriate and where a differentiated capsule can improve tolerability, acceptability, or access. A new excipient system alone is unlikely to justify a large price premium without a measurable patient or payer benefit.

What licensing and commercial opportunities exist for EVOXAC?

Publicly visible opportunities are more likely to involve regional commercialization, generic supply, or reformulation licensing than new active-ingredient licensing.

Potential deal structures include:

• Regional rights for a generic or branded-generic cevimeline capsule
• Contract manufacturing and supply agreements
• Licensing of an HPMC-capsule or lactose-free formulation
• Co-development of a liquid or orally disintegrating product
• Dual-source API and finished-dose supply arrangements
• Portfolio acquisitions involving Sjögren's syndrome and dry-eye or dry-mouth products

Revenue exposure is difficult to isolate because cevimeline sales are generally reported within broader product or regional categories rather than as a consistently disclosed standalone product line. The market is best viewed as a focused chronic-care opportunity with modest absolute revenue potential and potentially attractive margins for a disciplined generic or specialty supplier.

How strong is the EVOXAC patent estate?

The patent estate is weak for blocking a conventional U.S. generic capsule because the original active-ingredient and approval-era protections are old. A differentiated formulation could create new patent value, but protection would depend on demonstrable technical advantages such as:

• Improved stability
• Reduced capsule moisture transmission
• Controlled release
• Improved bioavailability
• Lower adverse-event exposure through pharmacokinetic control
• Enhanced swallowability
• Specific particle engineering or manufacturing processes

A patent directed only to substituting one routine filler for another would face a higher obviousness risk. Stronger protection would require a defined formulation architecture tied to measurable performance or clinical benefit.

Key Takeaways

• EVOXAC is a 30 mg immediate-release cevimeline hydrochloride hydrate capsule.
• The reference excipient system is conventional and includes lactose, hydroxypropyl cellulose, magnesium stearate, and a gelatin shell.
• A lactose-free, animal-origin-free generic is the clearest near-term formulation opportunity.
• HPMC capsules can support differentiation but introduce moisture, shell, and dissolution risks.
• The U.S. product is exposed to conventional generic competition; biosimilar risk does not apply.
• Original regulatory exclusivity and historical active-ingredient protection are no longer the main commercial barriers.
• Current FDA Orange Book status should control any Paragraph IV or freedom-to-operate analysis.
• API sourcing, capsule-fill uniformity, stability, and packaging are more important than complex patent strategy for a conventional generic.
• Modified-release, liquid, and orally disintegrating products offer higher differentiation but require materially greater regulatory and clinical investment.
• The commercial opportunity is niche and likely depends on reliable supply, low manufacturing cost, and targeted excipient differentiation rather than premium pricing.

FAQs

Can EVOXAC be reformulated without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, or another suitable filler-binder, provided the product meets quality, dissolution, stability, and bioequivalence requirements.

Is an HPMC capsule commercially preferable to a gelatin capsule for cevimeline?

It can be preferable for animal-origin-free positioning and selected institutional markets. The benefit must be weighed against higher development work involving shell moisture, brittleness, machine compatibility, and dissolution.

Does cevimeline have biosimilar competition?

No. Cevimeline is a small-molecule drug. Competing products would generally be generics, not biosimilars.

Could a once-daily cevimeline product receive new patent protection?

Potentially. A once-daily formulation could support new patent claims if it demonstrates a novel release system, meaningful pharmacokinetic control, or a clinically relevant advantage. Routine excipient substitution would provide weaker protection.

What is the most attractive first product for a generic manufacturer?

A 30 mg immediate-release capsule with a reference-like formulation, lactose-free fill, animal-origin-free HPMC shell, robust moisture-protective packaging, and dual-source API qualification offers the best balance of approval probability and commercial differentiation.

References

1. U.S. Food and Drug Administration. (2000). EVOXAC (cevimeline hydrochloride) capsules, prescribing information. Daiichi Sankyo, Inc.

2. National Library of Medicine. (n.d.). DailyMed: EVOXAC- cevimeline hydrochloride capsule. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. Center for Drug Evaluation and Research.

6. National Institute of Dental and Craniofacial Research. (2023). Sjögren's disease and dry mouth treatment resources. National Institutes of Health.